The effect of neoadjuvant Hormonal treatment in prostate cancer on biochemical recurrence

Korean Journal of Urology

Volumn 48, Issue 11, 2007, Pages 1125-1130

  Song, Kanghyon ^a   Park, Hongzoo ^a   Han, Ji Yeon ^a   You, Chang Hee ^a   Anh, Hanjong ^a   Kim, Choung Soo ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Neoadjuvant therapy; Prostate cancer; Recurrence

Indexed keywords

ANDROGEN; ANTIANDROGEN; GONADORELIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER STAGING; CASE CONTROL STUDY; CONTROLLED STUDY; GLEASON SCORE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PREOPERATIVE EVALUATION; PROSTATE CANCER; PROSTATECTOMY; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 36749074981     PISSN: 04944747     EISSN: None     Source Type: Journal    
DOI: 10.4111/kju.2007.48.11.1125     Document Type: Article

References (19)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, et al. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106-30
2. Cancer Registration and Biostatistics Branch, National Cancer Center. Cancer Statistics in Korea, 2003
3. Rosen MA, Goldstone L, Lapin S, Wheeler T, Scardino PT. Frequency and location of extracapsular extension and positive surgical margins in radical prostatectomy specimens. J Urol 1992;148:331-7
4. Bigg SW, Kavoussi LR, Catalona WJ. Role of nerve-sparing radical prostatectomy for clinical stage B2 prostate cancer. J Urol 1990;144:1420-4
5. Gleave ME, Goldenberg SL, Chin JL, Warner J, Saad F, Klotz LH, et al. Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects. J Urol 2001;166:500-6
6. Song J, Chang K. Current status of hormonal therapy for prostate cancer in Korea: a national survey of Korean urooncologists. Korean J Urol Oncol 2003;1:175-80
7. Park EK, Chung BH, Hong SJ. Influences of neoadjuvant androgen ablation before radical prostatectomy on positive surgical margin and biochemical recurrence rate. Korean J Urol 2004;45:518-23
8. Jones EC. Resection margin status in radical retropubic prostatectomy specimens: relationship to type of operation, tumor size, tumor grade and local tumor extension. J Urol 1990;144:89-93
9. Rosen MA, Goldstone L, Lapin S, Wheeler T, Scardino PT. Frequency and location of extracapsular extension and positive surgical margins in radical prostatectomy specimens. J Urol 1992;148:331-7
10. Partin AW, Yoo J, Carter HB, Pearson JD, Chan DW, Epstein JI, et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 1993;150:110-4
11. Lee HH, Warde P, Jewett MA. Neoadjuvant hormonal therapy in carcinoma of the prostate. BJU Int 1999;83:438-48
12. Pilepich MV, Krall JM, al-Sarraf M, John MJ, Doggett RL, Sause WT, et al. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group. Urology 1995;45:616-23
13. Schulman CC. Neoadjuvant androgen blockade prior to prostatectomy: a retrospective study and critical review. Prostate Suppl 1994;5:9-14
14. Soloway MS, Sharifi R, Wajsman Z, McLeod D, Wood DP Jr, Puras-Baez A. Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. The Lupron Depot Neoadjuvant Prostate Cancer Study Group. J Urol 1995;154:424-8
15. Goldenberg SL, Klotz LH, Srigley J, Jewett MA, Mador D, Fradet Y, et al. Randomized, prospective, controlled study comparing radical prostatectomy alone and neoadjuvant androgen withdrawal in the treatment of localized prostate cancer. Canadian Urologic Oncology Group. J Urol 1996;156: 873-7
16. Swindle P, Eastham JA, Ohori M, Kattan MW, Wheeler T, Maru N, et al. Do margins matter? The prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol 2005;174:903-7
17. Klotz LH, Goldenberg SL, Jewett M, Barkin J, Chetner M, Fradet Y, et al. CUOG randomized trial of neoadjuvant androgen ablation before radical prostatectomy: 36-month post-treatment PSA results. Canadian Urologic Oncology Group. Urology 1999;53:757-63
18. Meyer F, Moore L, Bairati I, Lacombe L, Tetu B, Fradet Y. Neoadjuvant hormonal therapy before radical prostatectomy and risk of prostate specific antigen failure. J Urol 1999; 162:2024-8
19. Lorente JA, Arango O, Bielsa O, Cortadellas R, Lloreta-Trull J, Gelabert-Mas A. A longer duration of neo-adjuvant combined androgen blockade prior to radical prostatectomy may lead to lower tumour volume of localised prostate cancer. Eur Urol 2003;43:119-23